0.8011
price down icon6.57%   -0.0563
after-market アフターアワーズ: .84 0.0389 +4.86%
loading
前日終値:
$0.8574
開ける:
$0.8444
24時間の取引高:
601.55K
Relative Volume:
0.74
時価総額:
$105.75M
収益:
$3.25M
当期純損益:
$-116.80M
株価収益率:
-0.2627
EPS:
-3.05
ネットキャッシュフロー:
$-98.17M
1週間 パフォーマンス:
-9.92%
1か月 パフォーマンス:
-29.73%
6か月 パフォーマンス:
-54.22%
1年 パフォーマンス:
-90.15%
1日の値動き範囲:
Value
$0.80
$0.8656
1週間の範囲:
Value
$0.80
$0.9748
52週間の値動き範囲:
Value
$0.7893
$8.58

Rapt Therapeutics Inc Stock (RAPT) Company Profile

Name
名前
Rapt Therapeutics Inc
Name
セクター
Healthcare (1181)
Name
電話
(650) 489-9000
Name
住所
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Name
職員
68
Name
Twitter
Name
次回の収益日
2024-11-11
Name
最新のSEC提出書
Name
RAPT's Discussions on Twitter

RAPT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RAPT
Rapt Therapeutics Inc
0.8011 105.75M 3.25M -116.80M -98.17M -3.05
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
485.89 124.91B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
549.28 60.05B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
587.59 35.88B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
230.50 29.83B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
228.14 24.58B 3.81B -644.79M -669.77M -6.24

Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-26 アップグレード H.C. Wainwright Neutral → Buy
2024-11-13 ダウングレード Stifel Buy → Hold
2024-11-11 ダウングレード JP Morgan Neutral → Underweight
2024-11-11 ダウングレード Piper Sandler Overweight → Neutral
2024-05-14 ダウングレード Wolfe Research Outperform → Peer Perform
2024-05-10 ダウングレード Barclays Overweight → Equal Weight
2024-05-10 ダウングレード Guggenheim Buy → Neutral
2024-02-22 ダウングレード UBS Buy → Neutral
2024-02-21 ダウングレード H.C. Wainwright Buy → Neutral
2024-02-21 ダウングレード JP Morgan Overweight → Neutral
2024-02-21 ダウングレード Leerink Partners Outperform → Market Perform
2024-02-20 ダウングレード Cantor Fitzgerald Overweight → Neutral
2024-02-16 開始されました Evercore ISI Outperform
2024-02-15 開始されました Wolfe Research Outperform
2023-09-14 開始されました Berenberg Buy
2023-08-09 開始されました Stifel Buy
2023-06-15 開始されました Barclays Overweight
2023-01-04 開始されました Guggenheim Buy
2022-12-01 開始されました Goldman Buy
2022-09-21 開始されました CapitalOne Overweight
2022-05-24 再開されました Cantor Fitzgerald Overweight
2021-12-09 開始されました JP Morgan Overweight
2021-08-12 開始されました SVB Leerink Outperform
2021-06-21 開始されました Piper Sandler Overweight
2020-06-01 開始されました H.C. Wainwright Buy
2020-05-19 開始されました Cantor Fitzgerald Overweight
2020-04-13 開始されました ROTH Capital Buy
2019-11-25 開始されました BMO Capital Markets Outperform
2019-11-25 開始されました UBS Buy
2019-11-25 開始されました Wells Fargo Outperform
すべてを表示

Rapt Therapeutics Inc (RAPT) 最新ニュース

pulisher
Apr 15, 2025

RAPT Therapeutics (RAPT) Strengthens Leadership with New VP for Clinical Development | RAPT Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

RAPT Therapeutics Deepens Expertise in Allergic Diseases - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Top Allergy Expert Joins RAPT to Accelerate Novel Food Allergy Treatment Pipeline - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co. - Defense World

Apr 13, 2025
pulisher
Mar 20, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN

Mar 19, 2025
pulisher
Mar 13, 2025

Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

H.C. Wainwright maintains $10 target on RAPT Therapeutics stock By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks

Mar 10, 2025
pulisher
Mar 07, 2025

RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 07, 2025
pulisher
Mar 07, 2025

Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan

Mar 07, 2025
pulisher
Mar 07, 2025

Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

RAPT THERAPEUTICS Earnings Results: $RAPT Reports Quarterly Earnings - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Rapt Therapeutics reports Q4 EPS ($1.14), consensus (36c) - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Can RAPT's $231M War Chest and New Food Allergy Drug Transform Its Future? - StockTitan

Mar 06, 2025
pulisher
Mar 03, 2025

RAPT Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView

Mar 03, 2025
pulisher
Feb 27, 2025

RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 23, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World

Feb 23, 2025
pulisher
Feb 16, 2025

Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha

Feb 16, 2025
pulisher
Feb 16, 2025

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Feb 16, 2025
pulisher
Feb 14, 2025

SG Americas Securities LLC Purchases 42,636 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

Feb 14, 2025
pulisher
Feb 12, 2025

Leerink Partnrs Has Positive Outlook of RAPT FY2024 Earnings - Armenian Reporter

Feb 12, 2025
pulisher
Feb 11, 2025

FY2024 Earnings Forecast for RAPT Issued By Leerink Partnrs - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy - Yahoo Finance

Feb 10, 2025
pulisher
Feb 08, 2025

RAPT Therapeutics Inc (NASDAQ: RAPT) Up 31.9% From 52-Week Low; YTD Falls -26.58% – Here’s What To Do Now - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 04, 2025

A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

A stock that deserves closer examination: Solidion Technology Inc (STI) - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

Analytical Lens: Exploring RAPT Therapeutics Inc (RAPT)’s Financial Story Through Ratios - The Dwinnex

Feb 04, 2025
pulisher
Jan 29, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Recommendation of “Hold” by Brokerages - Defense World

Jan 29, 2025
pulisher
Jan 28, 2025

Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com

Jan 28, 2025
pulisher
Jan 28, 2025

SEC Form 424B3 filed by RAPT Therapeutics Inc. - Quantisnow

Jan 28, 2025
pulisher
Jan 26, 2025

RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - MSN

Jan 26, 2025
pulisher
Jan 25, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stake Boosted by Barclays PLC - Defense World

Jan 25, 2025
pulisher
Jan 14, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by Jane Street Group LLC - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

RAPT Therapeutics Plans Phase 2b Trials for RPT904 - TipRanks

Jan 13, 2025
pulisher
Jan 10, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Purchased by Barclays PLC - Defense World

Jan 10, 2025
pulisher
Jan 09, 2025

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 09, 2025
pulisher
Jan 08, 2025

RAPT Therapeutics appoints new board chair By Investing.com - Investing.com Nigeria

Jan 08, 2025
pulisher
Jan 08, 2025

Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - insights.citeline.com

Jan 08, 2025
pulisher
Jan 06, 2025

RAPT Therapeutics appoints new board chair - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

RAPT Therapeutics, Inc. Announces Board Changes - Marketscreener.com

Jan 06, 2025
pulisher
Jan 06, 2025

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times

Jan 06, 2025
pulisher
Jan 06, 2025

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors - GlobeNewswire

Jan 06, 2025
pulisher
Jan 04, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $9.56 Average Target Price from Brokerages - MarketBeat

Jan 04, 2025

Rapt Therapeutics Inc (RAPT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$19.55
price up icon 0.21%
$70.20
price down icon 1.22%
$32.19
price down icon 0.80%
$23.05
price down icon 6.38%
$98.25
price down icon 0.76%
biotechnology ONC
$228.14
price down icon 4.48%
大文字化:     |  ボリューム (24 時間):